Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
ANN ARBOR, Mich., Dec 21, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that on December 20, 2007, the Company received a deficiency letter from The Nasdaq Stock Market indicating that the minimum
ANN ARBOR, Mich., Dec 7, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will participate in the Biomaterials: Helping The Body Regenerate
ANN ARBOR, Mich., Nov 29, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George Dunbar, President and Chief Executive Officer, will present at the 2007 BMO Capital Markets Focus on Healthcare
ANN ARBOR, Mich., Nov 05, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. First Quarter Fiscal Year 2008 Investor Conference Call When: Friday, November 9, 2007 @ 9:00 am (Eastern) Where:
ANN ARBOR, Mich., Oct 31, 2007 (BUSINESS WIRE) -- Aastrom Biosciences (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences Fiscal Year 2007 Annual Meeting of Shareholders When: Wednesday, November 7, 2007 @ 9:00 am (Eastern) Where: http://www.vcall.com/IC/CEPage.asp?ID=122044
ANN ARBOR, Mich., Oct 30, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that Gerald D. Brennan, Vice President, Administrative and Financial Operations and Chief Financial Officer and Elmar R.
Phase I/II Study Results Presented Today at the Orthopaedic Trauma Association Annual Meeting Show a Healing Rate of 91 Percent in Patients With Non-Union Tibia, Humerus or Femur Fractures Who Failed to Heal After One or More Medical Procedures
ANN ARBOR, Mich., Oct 16, 2007 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, announced today that it has executed definitive Purchase Agreements for the sale of approximately 11.8 million Units in a registered direct
ANN ARBOR, Mich., Oct 16, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial When: Monday, October 22, 2007 at 9:00 am (EDT) Where:
